Ionis Pharmaceuticals (IONS) Competitors $43.03 +0.05 (+0.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$42.98 -0.05 (-0.10%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, HALO, RGEN, and MDGLShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Repligen Madrigal Pharmaceuticals Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Is BIIB or IONS more profitable? Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Ionis Pharmaceuticals -28.25%-45.29%-8.99% Do analysts prefer BIIB or IONS? Biogen currently has a consensus target price of $185.63, indicating a potential upside of 40.68%. Ionis Pharmaceuticals has a consensus target price of $59.38, indicating a potential upside of 38.01%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Ionis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has stronger valuation and earnings, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.00$1.63B$10.1313.03Ionis Pharmaceuticals$944.05M7.27-$453.90M-$1.84-23.39 Do insiders & institutionals believe in BIIB or IONS? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, BIIB or IONS? Biogen has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Does the media refer more to BIIB or IONS? In the previous week, Biogen had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 49 mentions for Biogen and 25 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.85 beat Ionis Pharmaceuticals' score of 0.82 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 22 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBiogen beats Ionis Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.86B$2.51B$5.49B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-23.398.9728.8623.83Price / Sales7.27434.56371.4866.02Price / CashN/A157.7635.4557.96Price / Book10.874.838.275.54Net Income-$453.90M$31.62M$3.25B$259.28M7 Day Performance1.87%-5.28%-3.73%-4.68%1 Month Performance-1.28%4.38%4.29%4.36%1 Year Performance-12.42%-2.49%25.87%17.89% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.5458 of 5 stars$43.03+0.1%$59.38+38.0%-16.2%$6.86B$944.05M-23.391,069Trending NewsEarnings ReportAnalyst ForecastInsider TradeBIIBBiogen4.8444 of 5 stars$129.28-1.7%$186.37+44.2%-37.4%$18.94B$9.82B12.767,605Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionINCYIncyte4.7501 of 5 stars$70.16-0.1%$74.47+6.1%+17.3%$13.58B$4.24B219.262,617Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9639 of 5 stars$298.14-2.1%$383.08+28.5%-10.2%$13.45B$2.99B11.901,305Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap UpNBIXNeurocrine Biosciences4.6896 of 5 stars$133.71+1.2%$163.87+22.6%-15.8%$13.23B$2.36B45.331,800Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionEXELExelixis4.9491 of 5 stars$44.39-2.7%$45.33+2.1%+53.8%$12.11B$2.17B20.181,147Trending NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9771 of 5 stars$58.14-1.5%$93.74+61.2%-31.3%$11.15B$2.85B21.613,040News CoverageUpcoming EarningsEXASExact Sciences4.4246 of 5 stars$48.04-0.9%$70.50+46.8%-17.5%$9.06B$2.83B-8.727,000Positive NewsUpcoming EarningsHALOHalozyme Therapeutics4.775 of 5 stars$57.73-0.9%$62.70+8.6%+7.2%$7.11B$1.08B15.35390News CoveragePositive NewsUpcoming EarningsRGENRepligen4.6999 of 5 stars$119.65-1.7%$169.92+42.0%-28.2%$6.72B$634.44M-265.891,778Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionMDGLMadrigal Pharmaceuticals4.2783 of 5 stars$294.16-1.4%$420.63+43.0%+8.5%$6.53B$317.38M-16.3090News CoverageUpcoming Earnings Related Companies and Tools Related Companies BIIB Competitors INCY Competitors UTHR Competitors NBIX Competitors EXEL Competitors BMRN Competitors EXAS Competitors HALO Competitors RGEN Competitors MDGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
